The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Diabetic Retinopathy Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Diabetic retinopathy (die-uh-BET-ik ret-ih-NOP-uh-thee) is a diabetes complication that affects eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina).
The global Diabetic Retinopathy Treatment market size is expected to reach US$ 9807 million by 2029, growing at a CAGR of 4.5% from 2023 to 2029. The market is mainly driven by the significant applications of Diabetic Retinopathy Treatment in various end use industries. The expanding demands from the Ophthalmic Clinics, Ambulatory Surgical Centers, Hospitals and Other, are propelling Diabetic Retinopathy Treatment market. Proliferative Diabetic Retinopathy (PDR), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Proliferative Diabetic Retinopathy (NPDR) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Diabetic Retinopathy Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Diabetic Retinopathy Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Diabetic Retinopathy Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Diabetic Retinopathy Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Diabetic Retinopathy Treatment covered in this report include Regeneron Pharmaceuticals, ThromboGenics, Genentech, Bayer Healthcare, Alimera Sciences, Actavis, BCN Peptides, Novartis and Ampio Pharmaceuticals, etc.
The global Diabetic Retinopathy Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Regeneron Pharmaceuticals
ThromboGenics
Genentech
Bayer Healthcare
Alimera Sciences
Actavis
BCN Peptides
Novartis
Ampio Pharmaceuticals
Kowa Group
Sirnaomicsorporation
Abbott Laboratories
Glycadia Pharmaceuticals
Alcon Laboratories
Parexel International
Global Diabetic Retinopathy Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Diabetic Retinopathy Treatment market, Segment by Type:
Proliferative Diabetic Retinopathy (PDR)
Non-Proliferative Diabetic Retinopathy (NPDR)
Global Diabetic Retinopathy Treatment market, by Application
Ophthalmic Clinics
Ambulatory Surgical Centers
Hospitals
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Diabetic Retinopathy Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Diabetic retinopathy (die-uh-BET-ik ret-ih-NOP-uh-thee) is a diabetes complication that affects eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina).
The global Diabetic Retinopathy Treatment market size is expected to reach US$ 9807 million by 2029, growing at a CAGR of 4.5% from 2023 to 2029. The market is mainly driven by the significant applications of Diabetic Retinopathy Treatment in various end use industries. The expanding demands from the Ophthalmic Clinics, Ambulatory Surgical Centers, Hospitals and Other, are propelling Diabetic Retinopathy Treatment market. Proliferative Diabetic Retinopathy (PDR), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Proliferative Diabetic Retinopathy (NPDR) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Diabetic Retinopathy Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Diabetic Retinopathy Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Diabetic Retinopathy Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Diabetic Retinopathy Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Diabetic Retinopathy Treatment covered in this report include Regeneron Pharmaceuticals, ThromboGenics, Genentech, Bayer Healthcare, Alimera Sciences, Actavis, BCN Peptides, Novartis and Ampio Pharmaceuticals, etc.
The global Diabetic Retinopathy Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Regeneron Pharmaceuticals
ThromboGenics
Genentech
Bayer Healthcare
Alimera Sciences
Actavis
BCN Peptides
Novartis
Ampio Pharmaceuticals
Kowa Group
Sirnaomicsorporation
Abbott Laboratories
Glycadia Pharmaceuticals
Alcon Laboratories
Parexel International
Global Diabetic Retinopathy Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Diabetic Retinopathy Treatment market, Segment by Type:
Proliferative Diabetic Retinopathy (PDR)
Non-Proliferative Diabetic Retinopathy (NPDR)
Global Diabetic Retinopathy Treatment market, by Application
Ophthalmic Clinics
Ambulatory Surgical Centers
Hospitals
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Diabetic Retinopathy Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Diabetic Retinopathy Treatment
1.1 Diabetic Retinopathy Treatment Market Overview
1.1.1 Diabetic Retinopathy Treatment Product Scope
1.1.2 Diabetic Retinopathy Treatment Market Status and Outlook
1.2 Global Diabetic Retinopathy Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Diabetic Retinopathy Treatment Market Size by Region (2018-2029)
1.4 Global Diabetic Retinopathy Treatment Historic Market Size by Region (2018-2023)
1.5 Global Diabetic Retinopathy Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Diabetic Retinopathy Treatment Market Size (2018-2029)
1.6.1 North America Diabetic Retinopathy Treatment Market Size (2018-2029)
1.6.2 Europe Diabetic Retinopathy Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Diabetic Retinopathy Treatment Market Size (2018-2029)
1.6.4 Latin America Diabetic Retinopathy Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Diabetic Retinopathy Treatment Market Size (2018-2029)
2 Diabetic Retinopathy Treatment Market by Type
2.1 Introduction
2.1.1 Proliferative Diabetic Retinopathy (PDR)
2.1.2 Non-Proliferative Diabetic Retinopathy (NPDR)
2.2 Global Diabetic Retinopathy Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Diabetic Retinopathy Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Diabetic Retinopathy Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Diabetic Retinopathy Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Diabetic Retinopathy Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Diabetic Retinopathy Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Diabetic Retinopathy Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Diabetic Retinopathy Treatment Revenue Breakdown by Type (2018-2029)
3 Diabetic Retinopathy Treatment Market Overview by Application
3.1 Introduction
3.1.1 Ophthalmic Clinics
3.1.2 Ambulatory Surgical Centers
3.1.3 Hospitals
3.1.4 Other
3.2 Global Diabetic Retinopathy Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Diabetic Retinopathy Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Diabetic Retinopathy Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Diabetic Retinopathy Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Diabetic Retinopathy Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Diabetic Retinopathy Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Diabetic Retinopathy Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Diabetic Retinopathy Treatment Revenue Breakdown by Application (2018-2029)
4 Diabetic Retinopathy Treatment Competition Analysis by Players
4.1 Global Diabetic Retinopathy Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Diabetic Retinopathy Treatment as of 2022)
4.3 Date of Key Players Enter into Diabetic Retinopathy Treatment Market
4.4 Global Top Players Diabetic Retinopathy Treatment Headquarters and Area Served
4.5 Key Players Diabetic Retinopathy Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Diabetic Retinopathy Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Regeneron Pharmaceuticals
5.1.1 Regeneron Pharmaceuticals Profile
5.1.2 Regeneron Pharmaceuticals Main Business
5.1.3 Regeneron Pharmaceuticals Diabetic Retinopathy Treatment Products, Services and Solutions
5.1.4 Regeneron Pharmaceuticals Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Regeneron Pharmaceuticals Recent Developments
5.2 ThromboGenics
5.2.1 ThromboGenics Profile
5.2.2 ThromboGenics Main Business
5.2.3 ThromboGenics Diabetic Retinopathy Treatment Products, Services and Solutions
5.2.4 ThromboGenics Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 ThromboGenics Recent Developments
5.3 Genentech
5.3.1 Genentech Profile
5.3.2 Genentech Main Business
5.3.3 Genentech Diabetic Retinopathy Treatment Products, Services and Solutions
5.3.4 Genentech Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Bayer Healthcare Recent Developments
5.4 Bayer Healthcare
5.4.1 Bayer Healthcare Profile
5.4.2 Bayer Healthcare Main Business
5.4.3 Bayer Healthcare Diabetic Retinopathy Treatment Products, Services and Solutions
5.4.4 Bayer Healthcare Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Bayer Healthcare Recent Developments
5.5 Alimera Sciences
5.5.1 Alimera Sciences Profile
5.5.2 Alimera Sciences Main Business
5.5.3 Alimera Sciences Diabetic Retinopathy Treatment Products, Services and Solutions
5.5.4 Alimera Sciences Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Alimera Sciences Recent Developments
5.6 Actavis
5.6.1 Actavis Profile
5.6.2 Actavis Main Business
5.6.3 Actavis Diabetic Retinopathy Treatment Products, Services and Solutions
5.6.4 Actavis Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Actavis Recent Developments
5.7 BCN Peptides
5.7.1 BCN Peptides Profile
5.7.2 BCN Peptides Main Business
5.7.3 BCN Peptides Diabetic Retinopathy Treatment Products, Services and Solutions
5.7.4 BCN Peptides Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 BCN Peptides Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Diabetic Retinopathy Treatment Products, Services and Solutions
5.8.4 Novartis Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis Recent Developments
5.9 Ampio Pharmaceuticals
5.9.1 Ampio Pharmaceuticals Profile
5.9.2 Ampio Pharmaceuticals Main Business
5.9.3 Ampio Pharmaceuticals Diabetic Retinopathy Treatment Products, Services and Solutions
5.9.4 Ampio Pharmaceuticals Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Ampio Pharmaceuticals Recent Developments
5.10 Kowa Group
5.10.1 Kowa Group Profile
5.10.2 Kowa Group Main Business
5.10.3 Kowa Group Diabetic Retinopathy Treatment Products, Services and Solutions
5.10.4 Kowa Group Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Kowa Group Recent Developments
5.11 Sirnaomicsorporation
5.11.1 Sirnaomicsorporation Profile
5.11.2 Sirnaomicsorporation Main Business
5.11.3 Sirnaomicsorporation Diabetic Retinopathy Treatment Products, Services and Solutions
5.11.4 Sirnaomicsorporation Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Sirnaomicsorporation Recent Developments
5.12 Abbott Laboratories
5.12.1 Abbott Laboratories Profile
5.12.2 Abbott Laboratories Main Business
5.12.3 Abbott Laboratories Diabetic Retinopathy Treatment Products, Services and Solutions
5.12.4 Abbott Laboratories Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Abbott Laboratories Recent Developments
5.13 Glycadia Pharmaceuticals
5.13.1 Glycadia Pharmaceuticals Profile
5.13.2 Glycadia Pharmaceuticals Main Business
5.13.3 Glycadia Pharmaceuticals Diabetic Retinopathy Treatment Products, Services and Solutions
5.13.4 Glycadia Pharmaceuticals Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 Glycadia Pharmaceuticals Recent Developments
5.14 Alcon Laboratories
5.14.1 Alcon Laboratories Profile
5.14.2 Alcon Laboratories Main Business
5.14.3 Alcon Laboratories Diabetic Retinopathy Treatment Products, Services and Solutions
5.14.4 Alcon Laboratories Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.14.5 Alcon Laboratories Recent Developments
5.15 Parexel International
5.15.1 Parexel International Profile
5.15.2 Parexel International Main Business
5.15.3 Parexel International Diabetic Retinopathy Treatment Products, Services and Solutions
5.15.4 Parexel International Diabetic Retinopathy Treatment Revenue (US$ Million) & (2018-2023)
5.15.5 Parexel International Recent Developments
6 North America
6.1 North America Diabetic Retinopathy Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Diabetic Retinopathy Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Retinopathy Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Diabetic Retinopathy Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Retinopathy Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Diabetic Retinopathy Treatment Market Dynamics
11.1 Diabetic Retinopathy Treatment Industry Trends
11.2 Diabetic Retinopathy Treatment Market Drivers
11.3 Diabetic Retinopathy Treatment Market Challenges
11.4 Diabetic Retinopathy Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
